NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
Clinical Trials
13 trialsNCT04150289 2023-06-15
RECOMM
pharmaand GmbH
Completed
NCT00445068 2021-07-14
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Novartis
Phase 2 Terminated
NCT00532389 2020-12-19
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT00532675 2020-12-19
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Novartis
Phase 1 Completed
NCT02568943 2020-04-08
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Novartis
No longer available
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT02290431 2019-11-18
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Novartis
Phase 2 Completed
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT01083602 2017-12-21
MACS1271
Novartis
Phase 2 Completed
NCT02756663 2016-11-08
PANORAMA-5
Novartis
Phase 2 Withdrawn
NCT02204553 2016-01-05
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Novartis
No longer available
NCT00743288 2014-05-08
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Oncotherapeutics
Phase 1/2 Completed